logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2022
Mirum Pharmaceuticals Inc.
Top-line data readout phase III trial of Maralixibat(MARCH-PFIC)
Progressive Familial Intrahepatic Cholestasis in children
Q4 2022
X4 Pharmaceuticals, Inc.
Top-line results from Phase 3 trial of mavorixafor
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome
Q4 2022
Cyclo Therapeutics, Inc.
Interim analysis topline results from pivotal phase III study of Trappsol Cyclo
Niemann-Pick disease type C (NPC-1)
Q4 2022
Addex Therapeutics Ltd
Data from phase IIb/III study of Dipraglurant
Dyskinesia associated with Parkinson's disease
Q4 2022
Context Therapeutics Inc.
Final data from two phase 0 biomarker pharmacodynamic trials of ONA-XR
Breast cancer
Q4 2022
Gossamer Bio Inc.
Topline data from phase II trial of Seralutinib (TORREY )
Pulmonary Arterial Hypertension
Q4 2022
Gossamer Bio Inc.
36-week topline data from phase II clinical trial of GB004 (SHIFT-UC )
Active ulcerative colitis
Q4 2022
Eledon Pharmaceuticals, Inc.
Initial open label data from Phase 1b trial of Tegoprubart
Kidney transplantation
Q4 2022
Eledon Pharmaceuticals, Inc.
Initial open label data from Phase 2a trial of Tegoprubart
IgA Nephropathy
Q4 2022
Eledon Pharmaceuticals, Inc.
Initial open label data from Phase 2a trial of Tegoprubart
Islet Cell Transplantation for Type 1 Diabetes
Q4 2022
Impel Pharmaceuticals Inc.
Data readout from phase IIa proof-of concept study to evaluate the safety and efficacy of INP105
Autism spectrum disorder
Q4 2022
FEMASYS INC
Interim data from pivotal trial of FemaSeed (LOCAL)
Infertile
Q4 2022
Mirum Pharmaceuticals Inc.
Topline data from phase III trial of Livmarli (MARCH-PFIC)
Progressive familial intrahepatic cholestasis Type 2
Q4 2022
SELLAS Life Sciences Group, Inc.
Final data from phase I/II trial of Galinpepimut-S (GPS) in combination with Keytruda for up to 17 patients
Second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer
Q4 2022
Ascendis Pharma A/S
Topline data from phase I/II clinical trial of TransCon IL-2 ß/? (IL-ßelie?e)
advanced cancer
Q4 2022
Ascendis Pharma A/S
Topline data from phase II trial of TransCon CNP (ACcomplisH)
Achondroplasia (ages 2-10)

Q4 2022
Pharvaris N.V.
Topline data from phase II study of PHVS416 (RAPIDe-1)
On-demand treatment of HAE attacks
Q4 2022
Pharvaris N.V.
Topline data from phase II clinical trial of PHVS416 (CHAPTER-1)
Prophylactic treatment of HAE attacks
Q4 2022
Candel Therapeutics, Inc.
Data from phase 1b clinical trial of CAN-2409 in combination with Opdivo
1st line treatment in patients with newly diagnosed high-grade glioma
Q4 2022
Candel Therapeutics, Inc.
Data from phase I clinical trial of CAN-3110
Recurrent high-grade glioma
Q4 2022
Aligos Therapeutics, Inc
Top line results from 12-week cohort of phase I trial of ALG-000184
Healthy volunteers and chronic hepatitis B patients
Q4 2022
Frequency therapeutics
Data from phase IIb trial of FX-322
Sensorineural hearing loss
Q4 2022
Vera Therapeutics, Inc.
Primary endpoint data from phase IIb trial of Atacicept(ORIGIN)
IgA Nephropathy
Early Q4 2022
Tricida, Inc.
Topline results from phase IIIb study of Veverimer (VALOR-CKD)
Delaying chronic kidney disease progression in subjects with metabolic acidosis
Q4 2022
Rain Therapeutics Inc.
Interim data from phase II basket trial of Milademetan (MANTRA-2)
MDM2-amplified advanced solid tumors